A Phase 3 interventional study of Herpes Zoster vaccine (GSK 1437173A) in Herpes Zoster and Herpes Zoster Vaccine, sponsored by GlaxoSmithKline. Completed at 8 sites in 3 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-14.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Herpes Zoster by GlaxoSmithKline — 3 open to participants now, 5 under way, 1 of them phase 3. Herpes Zoster · GlaxoSmithKline.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 16th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2014, is one of 25 in phase 3, and was the 25th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →3 of the 44 studies in Herpes Zoster by GlaxoSmithKline are open now, in 7 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
GlaxoSmithKline · Sites in Belgium, France, Italy and 3 more countries
Ages 1–17
GlaxoSmithKline
Ages 50+
By country, each count listing its studies:
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 25 · Phase 4 2
First in 2007; this study’s year is marked. 4 started in 2014.
This study's enrollment of 651 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 450 across the 37 interventional studies, 448 across the 7 observational. Of the 39 that completed or were terminated, 34 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
1 of the studies in Herpes Zoster by GlaxoSmithKline that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of non- may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
Exclusion Criteria:
Acute disease and/or fever at the time of enrollment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
Biological: Herpes Zoster vaccine (GSK 1437173A)
Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
Biological: Herpes Zoster vaccine (GSK 1437173A)
Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
Biological: Herpes Zoster vaccine (GSK 1437173A)
2 doses administered intramuscularly in deltoid region of non-dominant arm.
Also known as: HZ/su vaccine
Number of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value
Anti-gE antibody concentrations, as determined by Enzyme-linked Immunosorbent Assay (ELISA). The cut-off value was ≥ 97 milli international units per milliliter (mIU/mL).
Time frame: At Month 3
Anti-gE Humoral Immunogenicity
Anti-gE antibody concentrations, were determined by ELISA, expressed as Geometric Mean Concentrations (GMCs), in milli international units per milliliter (mIU/mL).
Time frame: At Month 0 and Month 3
Number of Vaccine Responders for Anti-gE Concentrations as Determined by ELISA
Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.
Time frame: At Month 3
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest, that prevented normal every day activities.
Time frame: Within 7 days (Days 0-6) after each vaccine dose and across doses
Number of Days With Any Solicited Local Symptoms
The number of days with any local symptoms reported during the solicited post-vaccination period.
Time frame: During the 7 days (Days 0-6) after each vaccine dose
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, gastrointestinal (nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and temperature \[defined as oral temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature= temperature \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: Within 7 days (Days 0-6) after each vaccine dose and across doses
Number of Days With Any Solicited General Symptoms
The number of days with any general symptoms reported during the solicited post-vaccination period.
Time frame: During the 7 days (Days 0-6) after each vaccine dose
Number of Subjects With Any Potential Immune-Mediated Diseases (pIMDs)
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology
Time frame: From first vaccination up to 30 days post last vaccination (Month 0-Month 3) and from Month 4 until study end (Month 14)
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: During 30 days (Days 0-29) after each vaccination
Number of Subjects With Any Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From first vaccination up to 30 days post last vaccination (Month 0-Month 3) and from Month 4 to study end (Month 14)
| Milestone | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group |
|---|---|---|---|
| Started | 218 | 217 | 216 |
| Completed | 214 | 212 | 208 |
| Not completed | 4 | 5 | 8 |
| Withdrew: Serious adverse event | 1 | 1 | 1 |
| Withdrew: Non-serious adverse event | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 3 | 6 |
Anti-gE antibody concentrations, as determined by Enzyme-linked Immunosorbent Assay (ELISA). The cut-off value was ≥ 97 milli international units per milliliter (mIU/mL).
| Subjects | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group |
|---|---|---|---|
| Number of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value | 210 | 210 | 202 |
Anti-gE antibody concentrations, were determined by ELISA, expressed as Geometric Mean Concentrations (GMCs), in milli international units per milliliter (mIU/mL).
| mIU/mL | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group |
|---|---|---|---|
| Anti-gE, Month 0 | 1378.4 (1180.0 to 1610.0) | 1166.5 (1005.5 to 1353.4) | 1381.2 (1190.9 to 1601.9) |
| Anti-gE, Month 3 | 59556.1 (54587.6 to 64976.7) | 60733.8 (55995.2 to 65873.3) | 62058.3 (57422.3 to 67068.7) |
Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x97 mIU/mL); For initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.
| Subjects | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group |
|---|---|---|---|
| Number of Vaccine Responders for Anti-gE Concentrations as Determined by ELISA | 201 | 205 | 197 |
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest, that prevented normal every day activities.
| Subjects | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group |
|---|---|---|---|
| Any Pain, Dose 1 | 160 | 179 | 166 |
| Grade 3 Pain, Dose 1 | 4 | 6 | 7 |
| Any Redness, Dose 1 | 29 | 48 | 41 |
| Grade 3 Redness, Dose 1 | 1 | 1 | 1 |
| Any Swelling, Dose 1 | 24 | 33 | 26 |
| Grade 3 Swelling, Dose 1 | 0 | 0 | 1 |
| Any Pain, Dose 2 | 155 | 152 | 155 |
| Grade 3 Pain, Dose 2 | 18 | 13 | 7 |
| Any Redness, Dose 2 | 38 | 47 | 43 |
| Grade 3 Redness, Dose 2 | 3 | 2 | 2 |
| Any Swelling, Dose 2 | 22 | 28 | 25 |
| Grade 3 Swelling, Dose 2 | 3 | 1 | 1 |
| Any Pain, Across Doses | 188 | 196 | 185 |
| Grade 3 Pain, Across Doses | 22 | 16 | 13 |
| Any Redness, Across Doses | 52 | 68 | 62 |
| Grade 3 Redness, Across Doses | 4 | 3 | 3 |
| Any Swelling, Across Doses | 38 | 44 | 39 |
| Grade 3 Swelling, Across Doses | 3 | 1 | 2 |
The number of days with any local symptoms reported during the solicited post-vaccination period.
| Days | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group |
|---|---|---|---|
| Pain post-Dose 1 | 2.0 (2.0 to 3.5) | 3.0 (2.0 to 3.0) | 3.0 (2.0 to 4.0) |
| Pain post-Dose 2 | 2.0 (2.0 to 4.0) | 2.0 (2.0 to 3.0) | 2.0 (2.0 to 3.0) |
| Redness post-Dose 1 | 2.0 (2.0 to 3.0) | 3.0 (1.5 to 3.0) | 2.0 (2.0 to 4.0) |
| Redness post-Dose 2 | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 3.0) | 3.0 (2.0 to 3.0) |
| Swelling post-Dose 1 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) | 3.0 (2.0 to 4.0) |
| Swelling post-Dose 2 | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 4.0) | 3.0 (2.0 to 3.0) |
Assessed solicited general symptoms were fatigue, gastrointestinal (nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and temperature \[defined as oral temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 temperature= temperature \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Subjects | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group |
|---|---|---|---|
| Any Fatigue, Dose 1 | 66 | 68 | 64 |
| Grade 3 Fatigue, Dose 1 | 5 | 4 | 4 |
| Related Fatigue, Dose 1 | 62 | 63 | 58 |
| Any Gastrointestinal, Dose 1 | 23 | 22 | 26 |
| Grade 3 Gastrointestinal, Dose 1 | 1 | 0 | 4 |
| Related Gastrointestinal, Dose 1 | 19 | 20 | 23 |
| Any Headache, Dose 1 | 63 | 68 | 49 |
| Grade 3 Headache, Dose 1 | 5 | 4 | 4 |
| Related Headache, Dose 1 | 59 | 63 | 43 |
| Any Myalgia, Dose 1 | 85 | 89 | 76 |
| Grade 3 Myalgia, Dose 1 | 4 | 3 | 4 |
| Related Myalgia, Dose 1 | 71 | 78 | 62 |
| Any Shivering, Dose 1 | 31 | 21 | 22 |
| Grade 3 Shivering, Dose 1 | 1 | 4 | 0 |
| Related Shivering, Dose 1 | 30 | 19 | 21 |
| Any Temperature, Dose 1 | 28 | 23 | 22 |
| Grade 3 Temperature, Dose 1 | 0 | 0 | 0 |
| Related Temperature, Dose 1 | 24 | 21 | 19 |
| Any Fatigue, Dose 2 | 91 | 85 | 82 |
| Grade 3 Fatigue, Dose 2 | 14 | 7 | 6 |
| Related Fatigue, Dose 2 | 89 | 80 | 76 |
| Any Gastrointestinal, Dose 2 | 33 | 34 | 29 |
| Grade 3 Gastrointestinal, Dose 2 | 2 | 2 | 5 |
| Related Gastrointestinal, Dose 2 | 29 | 29 | 28 |
| Any Headache, Dose 2 | 74 | 80 | 66 |
| Grade 3 Headache, Dose 2 | 9 | 11 | 5 |
| Related Headache, Dose 2 | 69 | 76 | 63 |
| Any Myalgia, Dose 2 | 99 | 91 | 83 |
| Grade 3 Myalgia, Dose 2 | 20 | 11 | 7 |
| Related Myalgia, Dose 2 | 85 | 81 | 76 |
| Any Shivering, Dose 2 | 67 | 60 | 44 |
| Grade 3 Shivering, Dose 2 | 11 | 5 | 7 |
| Related Shivering, Dose 2 | 66 | 59 | 43 |
| Any Temperature, Dose 2 | 43 | 34 | 25 |
| Grade 3 Temperature, Dose 2 | 2 | 0 | 1 |
| Related Temperature, Dose 2 | 40 | 33 | 25 |
| Any Fatigue, Across Doses | 114 | 109 | 107 |
| Grade 3 Fatigue, Across Doses | 18 | 11 | 10 |
| Related Fatigue, Across Doses | 111 | 102 | 103 |
| Any Gastrointestinal, Across Doses | 46 | 45 | 50 |
| Grade3 Gastrointestinal,Across Doses | 3 | 2 | 9 |
| Any Headache, Across Doses | 101 | 108 | 89 |
| Grade 3 Headache, Across Doses | 13 | 13 | 9 |
| Related Headache, Across Doses | 95 | 101 | 82 |
| Any Myalgia, Across Doses | 128 | 119 | 113 |
| Grade 3 Myalgia, Across Doses | 24 | 12 | 10 |
| Related Myalgia, Across Doses | 112 | 107 | 102 |
| Any Shivering, Across Doses | 80 | 67 | 60 |
| Grade 3 Shivering, Across Doses | 12 | 7 | 7 |
| Related Shivering, Across Doses | 79 | 65 | 58 |
| Any Temperature, Across Doses | 59 | 49 | 43 |
| Grade 3 Temperature, Across Doses | 2 | 0 | 1 |
| Related Temperature, Across Doses | 53 | 46 | 41 |
| Related Gastrointestinal, Across Doses | 41 | 39 | 46 |
The number of days with any general symptoms reported during the solicited post-vaccination period.
| Days | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group |
|---|---|---|---|
| Fatigue post-Dose 1 | 2.0 (1.0 to 2.0) | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| Fatigue post-Dose 2 | 2.0 (1.0 to 2.0) | 2.0 (1.0 to 3.0) | 1.5 (1.0 to 2.0) |
| Gastrointestinal symptoms post-Dose 1 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
| Gastrointestinal symptoms post-Dose 2 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
| Headache post-Dose 1 | 1.0 (1.0 to 2.0) | 1.5 (1.0 to 2.0) | 2.0 (1.0 to 3.0) |
| Headache post-Dose 2 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) | 2.0 (1.0 to 3.0) |
| Myalgia post-Dose 1 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| Myalgia post-Dose 2 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| Shivering post-Dose 1 | 1.0 (1.0 to 2.0) | 2.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
| Shivering post-Dose 2 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 1.5) | 1.0 (1.0 to 2.0) |
| Temperature post-Dose 1 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 1.0) |
| Temperature post-Dose 2 | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 2.0) |
Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology
| Subjects | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group |
|---|---|---|---|
| pIMDs from Month 0 to Month 3 | 3 | 0 | 1 |
| pIMDs from Month 4 to Month 14 | 2 | 0 | 2 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Subjects | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group |
|---|---|---|---|
| Any AE(s) | 72 | 69 | 76 |
| Grade 3 AE(s) | 13 | 15 | 9 |
| Related AE(s) | 23 | 22 | 27 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Subjects | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group |
|---|---|---|---|
| SAEs from Month 0 to Month 3 | 5 | 7 | 4 |
| SAEs from Month 4 to Month 14 | 10 | 8 | 16 |
Collected over Solicited local and general symptoms: within 7 days (Days 0-6) after each vaccination; Unsolicited AEs: during 30 days (Days 0-29) after each vaccination; SAEs: from first vaccination up to study end (Month 0-Month 14).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK1437173A Lot A Group | — | 13/218 (6%) | 202/218 (92.7%) |
| GSK1437173A Lot B Group | — | 14/217 (6.5%) | 201/217 (92.6%) |
| GSK1437173A Lot C Group | — | 20/216 (9.3%) | 198/216 (91.7%) |
| Event | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group |
|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 2/218 | 0/217 | 2/216 |
| SepsisInfections and infestations | 0/218 | 2/217 | 1/216 |
| Back painMusculoskeletal and connective tissue disorders | 0/218 | 2/217 | 0/216 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/218 | 2/217 | 0/216 |
| CholelithiasisHepatobiliary disorders | 2/218 | 1/217 | 0/216 |
| LeukocytosisBlood and lymphatic system disorders | 0/218 | 0/217 | 1/216 |
| Acute myocardial infarctionCardiac disorders | 1/218 | 0/217 | 1/216 |
| Myocardial infarctionCardiac disorders | 0/218 | 0/217 | 1/216 |
| Sinus node dysfunctionCardiac disorders | 0/218 | 0/217 | 1/216 |
| Supraventricular tachycardiaCardiac disorders | 0/218 | 0/217 | 1/216 |
| Event | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group |
|---|---|---|---|
| PainGeneral disorders | 188/218 | 196/217 | 185/216 |
| MyalgiaMusculoskeletal and connective tissue disorders | 128/218 | 119/217 | 113/216 |
| FatigueGeneral disorders | 114/218 | 109/217 | 107/216 |
| HeadacheNervous system disorders | 101/218 | 108/217 | 89/216 |
| ChillsGeneral disorders | 80/218 | 67/217 | 61/216 |
| ErythemaSkin and subcutaneous tissue disorders | 55/218 | 70/217 | 62/216 |
| PyrexiaGeneral disorders | 60/218 | 50/217 | 43/216 |
| Gastrointestinal disorderGastrointestinal disorders | 46/218 | 45/217 | 50/216 |
| SwellingGeneral disorders | 38/218 | 44/217 | 40/216 |
| Upper respiratory tract infectionInfections and infestations | 7/218 | 7/217 | 11/216 |
| Age, Continuous(Years) | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group | Total |
|---|---|---|---|---|
| Mean | 64.8 ± 8.8 | 64.3 ± 9.4 | 64.4 ± 8.8 | 64.5 ± 8.99 |
| Sex: Female, Male(Participants) | GSK1437173A Lot A Group | GSK1437173A Lot B Group | GSK1437173A Lot C Group | Total |
|---|---|---|---|---|
| Female | 116 | 130 | 114 | 360 |
| Male | 102 | 87 | 102 | 291 |
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Aug 2014 to primary completion in Apr 2015, 8 months.
Results were first posted in May 2017, 2 years after primary completion. A results delay was requested in Nov 2015.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 8 months is below that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Herpes Zoster Vaccine